Literature DB >> 9067972

Generation of antiserum to specific epitopes.

D C Marchion1, D S Manning, W M Shafer, R C Judd.   

Abstract

The ability to prevent disease by immunization with subunit vaccines that incorporate specific epitopes was demonstrated by DiMarchi et al. (1), who used a synthetic peptide to protect cattle against foot-and-mouth disease. However, generation of antibody to peptide antigens is often difficult owing to the small molecular mass and limited chemical complexity. We tested the hypothesis that recombinant DNA and synthetic peptide techniques would make it possible to stimulate vigorous immune responses to specific epitopes of an outer membrane protein of Neisseria gonorrhoeae. The MtrC AP1 sequence from the invariant MtrC gonococcal lipoprotein was genetically fused to maltose binding protein. The resultant fusion protein was used as the primary immunogen to stimulate MtrC AP1-specific antiserum. To enhance antibody production specific to MtrC AP1, boosting immunizations were performed with synthetic MtrC AP1 sequence contained in a multiple antigenic peptide system immunogen. The MtrC AP1-specific antiserum strongly recognized the MtrC protein on Western blots and appeared to bind native MtrC protein in situ. The generation of antibody in this fashion provides the technology to produce antibody to defined epitopes of any protein, including those found in the gonococcal outer membrane. The ability of those antibodies to inhibit bacterial growth or to activate complement protein can then be tested.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9067972     DOI: 10.1007/BF02761705

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  16 in total

Review 1.  Molecular mechanisms of antigenic variation in Neisseria gonorrhoeae.

Authors:  H S Seifert
Journal:  Mol Cell Biol Hum Dis Ser       Date:  1992

2.  Potential use of live viral and bacterial vectors for vaccines. WHO meeting, Geneva, 19-22 June, 1989.

Authors: 
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

3.  Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase.

Authors:  G M Air; W G Laver; R G Webster
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  The role of direct oligonucleotide repeats in gonococcal pilin gene variation.

Authors:  S A Hill; S G Morrison; J Swanson
Journal:  Mol Microbiol       Date:  1990-08       Impact factor: 3.501

Review 5.  Vaccine technologies: view to the future.

Authors:  N R Rabinovich; P McInnes; D L Klein; B F Hall
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

6.  Factors promoting pathogenicity of influenza virus.

Authors:  P J Anderson
Journal:  Semin Respir Infect       Date:  1991-03

7.  Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system.

Authors:  K E Hagman; W Pan; B G Spratt; J T Balthazar; R C Judd; W M Shafer
Journal:  Microbiology       Date:  1995-03       Impact factor: 2.777

8.  Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.

Authors:  J E Morin; M D Lubeck; J E Barton; A J Conley; A R Davis; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

9.  Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs.

Authors:  M V Chengalvala; B M Bhat; R Bhat; M D Lubeck; S Mizutani; A R Davis; P P Hung
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

10.  Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.

Authors:  R E Black; M M Levine; M L Clements; G Losonsky; D Herrington; S Berman; S B Formal
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.